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Abstract
Background Laser interstitial thermal therapy (LITT) under magnetic resonance imaging (MRI) monitoring is being increasingly used in cytoreductive surgery of recurrent brain tumors and tumors located in eloquent brain areas. The objective of
this study was to adapt this technique to an animal glioma model.
Methods A rat model of U251 glioblastoma (GBM) was employed. Tumor location and extent were determined by MRI
and dynamic contrast-enhanced (DCE) MRI. A day after assessing tumor appearance, tumors were ablated during diffusionweighted imaging (DWI)-MRI using a Visualase LITT system (n = 5). Brain images were obtained immediately after ablation
and again at 24 h post-ablation to confirm the efficacy of tumor cytoablation. Untreated tumors served as controls (n = 3).
Rats were injected with fluorescent isothiocyanate (FITC) dextran and Evans blue that circulated for 10 min after post-LITT
MRI. The brains were then removed for fluorescence microscopy and histopathology evaluations using hematoxylin and
eosin (H&E) and major histocompatibility complex (MHC) staining.
Results All rats showed a space-occupying tumor with T2 and T1 contrast-enhancement at pre-LITT imaging. The rats
that underwent the LITT procedure showed a well-demarcated ablation zone with near-complete ablation of tumor tissue
and with peri-ablation contrast enhancement at 24 h post-ablation. Tumor cytoreduction by ablation as seen on MRI was
confirmed by H&E and MHC staining.
Conclusions Data showed that tumor cytoablation using MRI-monitored LITT was possible in preclinical glioma models.
Real-time MRI monitoring facilitated visualizing and controlling the area of ablation as it is otherwise performed in clinical
applications.
Keywords Cytoreductive surgery · Diffusion-weighted imaging · High-grade glioma · Laser interstitial thermal therapy ·
Tumor ablation · U251 glioma
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with a 2-year survival rate of 30% [17]. Current standard
therapy uses a combination of maximal surgical resection
followed by radiotherapy and chemotherapy, primarily
temozolomide [33]. It is known that the extent of resection
(EOR) is directly proportional to the delay in recurrence.
Preclinical research reports with resected glioma models
are few and, with deep-seated experimental tumors being
inaccessible [9], restricted to cortical location [10, 11, 34].
Safe maximal tumor resection being the goal, intra-operative
tumor visualization techniques are being increasingly used
for glioma resection in the clinic [23]. To our knowledge,
however, imaging-guided cytoreduction/tumor debulking
that can be applied to even subcortical tumors has not been
reported in preclinical glioma models.
Laser interstitial thermal therapy (LITT) is an emerging minimally invasive procedure used for its cytoreductive
capabilities to treat GBMs, as well as radiation necrosis and
epilepsy [6]. Thermal energy is emitted from a laser fiber
inserted into the brain to ablate the lesioned tissue under
magnetic resonance imaging (MRI)-guided real-time monitoring. Tissue is ablated due to coagulative necrosis via
quick heating. LITT has been used for deep-seated lesions
that would normally be inaccessible via a craniotomy or
might invade eloquent structures [5, 18, 20, 27, 29, 30].
The objective of this study was to adapt and perform realtime imaging-guided LITT in an animal model in order to
replicate the clinical scenario. A rat model of U251 glioblastoma was used, and a Visualase (Medtronic, Inc., Minneapolis, MN) clinical laser system was employed under
diffusion-weighted imaging (DWI)-MRI guidance for tumor
ablation. Since the objective was to establish feasibility and
efficacy of the clinical system under a laboratory setting,
the study was designed to assess tumor ablation at acute
times, and, thus, the rats were sacrificed 24 h after ablation
for histopathology.

Materials and methods
The Visualase® apparatus was a kind gift from Medtronic,
Inc. (Minneapolis, MN, USA). All other materials used were
of pharmaceutical or analytical grade.

Visualase LITT system
The clinical Visualase LITT system (Medtronic Inc., Minneapolis, MN) utilizes a saline-cooled diode laser (diameter = 0.64 mm) with a near-infrared (980 nm) wavelength.
This wavelength has a high water absorption coefficient,
which produces rapid heating and a sharply delineated
ablation zone. Instantaneous cell death through coagulative necrosis occurs at 60 °C. At temperatures between
43 and 60 °C, a combination of time and temperature
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results in cell death primarily through apoptosis. Concurrent MR thermometry allows precise delineation of ablation boundaries. The lesion created is typically conformal
to the boundaries of the tumor tissue; natural heat sinks,
such as adjacent sulci, cisterns and perfusion prevent heat
propagation to potentially eloquent structures. Compared
to relatively high energy settings of 9–12 V and duration
of several minutes used for human tumor ablation, a low
energy setting of 1 V and a duration of about 30–40 s were
used for MRI-guided rat glioma ablation.

U251 rat model of orthotopic glioma
All experimental procedures were approved by the Institutional Animal Care and Use Committee (protocol IACUC
#1509). Adult female, immune-compromised, RNU/RNU
rats (n = 9) were intracerebrally implanted as follows:
animals were anesthetized with isoflurane (4% for induction, 1.5 to 2.0% for maintenance, balance N
 2O:O2 = 2:1).
The scalp was swabbed with Betadine and alcohol, the
eyes coated with Lacri-lube and the head immobilized in
a small animal stereotactic device (Kopf, Cayunga, CA).
After sterile draping, a 1-cm incision was made 2 mm
right of the midline and the skull exposed. A burr hole
was drilled 3.50 mm to the right of bregma (anterioposterior = 0.0), without penetrating the dura. A #2701
10-μl Hamilton syringe with a 26-gauge needle containing freshly harvested U251 tumor cells from log phase
growth (5 × 105 cells in 10 μl of phosphate buffered saline)
was lowered to a depth of 3.0 mm and then raised back to a
depth of 2.5 mm. Cells were injected at a rate of 0.5 μl/10 s
until the entire volume was used. The needle was left in
place for 5 min more and then gently withdrawn, the burr
hole sealed with sterile bone wax and the scalp incision
closed [8, 12, 24].

MRI studies
Imaging studies were performed to measure tumor location and extent about 2 weeks after tumor implantation
following published techniques [3, 8, 12, 25]. Briefly, each
animal was anesthetized with isoflurane (4% for induction, 0.75 to 1.5% for maintenance, balance N2O:O2 = 2:1)
and allowed to spontaneously respire. A tail vein was cannulated for magnetic resonance contrast agent (MRCA)
administration. Body temperature was maintained at 37 °C
with warm air and monitored via an intrarectal probe. Two
complete MRI studies were conducted with an interval of
48 h between them and the LITT done at 24 h after the first
imaging session (refer to Appendix and references therein
for complete details on MRI methods and data analysis).
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A diffusion-weighted imaging (DWI) sequence was used for
tumor ablation and its visualization for performing the LITT
procedure. Following published procedures, a pre-MRI
study was done 2 weeks after tumor implantation (when the
tumor reached about 4 mm in diameter) and 24 h prior to
the tumor ablation study. Cerebral blood flow (CBF), diffusion, T2-weighted and T1 images and two Look Locker (LL)
sequences were acquired. Tumor extent was estimated using
a data-driven model selection analysis applied to dynamic
contrast-enhanced (DCE)-MRI, in which the tumor region
displayed extravasation and an approach to equilibrium with
the vascular concentration of the contrast agent, Magnevist
(Bayer HealthCare Pharmaceuticals, Wayne, NJ). Two more
Look Looker and post-contrast T1-weighted images were
acquired after DCE-MRI.
The first MRI study was done to localize and measure
the tumor extent. The LITT procedure was performed 24 h
later. We adapted the Visualase LITT system used in human
surgeries for rat tumor ablation. Using the pre-LITT MR
images, it was determined whether the burr hole made to
implant tumor cells could be re-bored to insert the laser fiber
or a new burr hole needed to be made if the bulk of the
tumor was not located directly under the original hole. The
rat was anesthetized using the isoflurane:N2O:O2 inhalation
mixture and its head fixed in a rat stereotactic frame. The
scalp was cleaned with betadine and alcohol swabs, and a
1.5-cm incision was made just right of midline. The underlying fascia and bone were cleaned with sterile cotton swabs.
Either the original burr hole was re-drilled or a new burr
hole made directly above the tumor mass as seen on MRI.
The rat was then placed in the MRI holder with a nose cone

for delivering anesthetic gases. Ear bars were inserted to
keep the head flat and to prevent moving and body temperature monitored by a rectal probe.
The LITT procedure was performed inside the MRI
volume coil that allowed the insertion of the laser fiber.
A ~ 90-cm-long plastic tube with an internal diameter of
2.50 mm bent at 90° angle at one end was affixed onto the
plexiglass imaging holder with its tip just above the burr
hole (Fig. 1). A laser fiber with a 3-mm tip connected to the
Visualase system was threaded through this tube, lowered
into the brain and positioned in the center of the tumor mass.
The holder was then slid inside the volume coil for imaging, and T1-weighted images were used to localize the fiber
and make sure it was inside the tumor. The spin-echo DWI
sequence with a b value of 912 s/mm2 was set with an echo
time of 29.03 ms, repetition time 400 ms, with 4 averages
and 55 repetitions with single slice of 2-mm thickness in a
32 × 32 mm field of view. Once the imaging parameters were
set, the DWI sequence was begun, and baseline images were
collected for 30 s at which time the ablation was started.
The DWI image was visually monitored, and laser firing/
ablation was stopped when the DWI signal/ablation covered
the tumor (refer to the video in Supplementary Data file for
an example). The DWI sequence was allowed to run its full
course of 4 min 24 s. The plexiglass holder was then pulled
back from the MRI apparatus, the laser fiber gently withdrawn, and the ear bars and temperature probe were removed
from the rat. The burr hole was then sealed with sterile bone
wax and the scalp incision closed with sterile silk sutures.
Pre-contrast and post-contrast T1-weighted images were
acquired using the head coil, and the rat was allowed to
recover. Another complete MRI study was performed 24 h
after LITT and the rat sacrificed for histopathology.

Fig. 1  Assembling the anesthetized rat and the laser interstitial thermal therapy fiber for tumor ablation. Panel A shows the rat with the
nose cone for delivering anesthetic gases, ear bars and rectal temperature monitor. A broad, semi-circle shaped plastic holder was
taped to the top of the plexiglass imaging holder (B). The plastic tube
was threaded through the magnetic resonance imaging (MRI) holder

and inserted into the underside of the plastic holder and its opening
positioned over the pre-drilled burr hole (C). The tube was held in
place by plastic fasteners. Panel D shows a close up of the laser fiber
inserted into the brain before sliding the whole assembly into the
bore of the magnet inside the volume coil for visualizing the extent of
ablation in real time under diffusion-weighted imaging—MRI

DWI‑LITT procedure
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Histopathology
The rats were maintained on a deep isoflurane anesthesia
after the post-LITT 24-h MRI session. A cocktail of Evans
Blue ([EB]; 1 ml of a 2% solution) and fluorescent isothiocyanate (FITC)-dextran (2000 kDa; 1 ml of 50 mg/ml) was
injected through the tail vein cannula. It was allowed to
circulate for 10 min, the rat was then decapitated and the
brain quickly removed and stored at 4 °C in 10% paraformaldehyde solution. After 48 h of immersion fixation, the
brain was cut into 2-mm-thick slabs in a rat brain matrix.
One 2-mm-thick slab with tumor tissue was further cut into
100-μm-thick slices in a vibratome, and these slices were
mounted in a glycerin-based mounting medium on glass
slides, coverslipped and sealed with clear nail polish to keep
the slices hydrated. The slides were stored at 4 °C until fluorescence microscopy.
The other slab with tumor tissue was embedded in paraffin and then cut into 6-μm-thick sections. These sections
were used for staining with hematoxylin and eosin (H&E)
to confirm tissue necrosis, major histocompatibility complex (MHC) to localize tumor cells [26] and glial fibrillary
acidic protein (GFAP) to evaluate heating-induced gliosis.
For GFAP staining, the sections were cleared and rehydrated
through several changes of xylene and a series of graded
alcohols. Antigen retrieval was done at 95 °C for 45 min in
Biocare’s Decloaking chamber using Diva Decloaker (Biocare DV2004G1). Sections were then blocked for 5 min in
Peroxidase (Biocare IPB5000L) and for 20 min in Rodent
Block R (Biocare RBR962L). A 30-min incubation with
a 1:1200 dilution of GFAP (Abcam 33,922) was followed
by 20 min in Rabbit on Rodent HRP Polymer (Biocare
RMR622L). DAB (Biocare IPK5010G80) was then applied
to sections for 4 min. Counterstaining was completed using
hematoxylin (Biocare IPCS5006L) for 3 min.

Fluorescence microscopy
A Keyence All-in-One Fluorescence Microscope BZ-X800
(Keyence Corporation of America, Itasca, IL) was used
for fluorescence microscopy. The vibratome sections were
scanned with a 2 × objective with a numerical aperture of
0.1 and an approximate depth of field of 55 µm. Subsequent
microscopic data were acquired using a 20 × objective with
a numerical aperture of 0.75 and approximate depth of field
of 1.0 µm to examine the peri-lesional area in greater detail.
For image acquisition, 20% excitation light was used with
a 3–3.5 s and 1/7.5–1/8.5 s brightness exposure for the
2 × and 20 × lens, respectively. The red EB and green FITC
fluorochromes in the sections were excited by a laser beam
at 560 nm and 470 nm, respectively, with corresponding
absorption wavelengths of 630 nm and 525 nm. The red
and green fluorophore images were merged using Keyence
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BZ-X800 analyzer software (Keyence, Osaka, Japan) to visualize the peri-ablation microvasculature and to examine the
relative distributions of the two plasma-borne tracers.

Data analysis
The MRI data were processed offline to produce quantitative
parameter maps following published procedures. Values for
the DCE-MRI parameters were estimated for the pre-LITT
and post-LITT sessions. The post-LITT maps and T1 subtraction as well as CBF images were used to verify the location and extent of tumor by comparing them to the terminal
histology images. The fluorescence images were examined
qualitatively for tracer leakage patterns in the peri-ablation
zone.

Results
The pre-LITT MRI data showed an embedded tumor located
subcortically in the striatal region. Such known phenotypic
features of a U251 glioma as a space-occupying tumor with
mass effect, contrast enhancement and peri-tumoral edema
were observed (Fig. 2; first row, top panel). The area of
enhancement was confined to the peri-ablation area immediately after LITT (Fig. 2; second row, top panel). Compared
to the pre-LITT images, the post-LITT T1-weighted images
showed a central area of tissue loss with peri-ablation contrast enhancement (Fig. 2; third row, top panel) with little
blood flow in the ablated region. The terminal histologies
confirmed the post-LITT MRI data and showed the ablation
of the bulk of the tumor on H&E, MHC and fluorescence
images (Fig. 2; middle panel). Fluorescence microscopy
showed that vasculature around the ablation zone was intact
for FITC-dextran (2000 kDa), but extravascular presence
of EB (tagged to plasma albumin, ~ 68 kDa) was seen suggesting size-specific leakage of blood-borne substrates of
relatively high molecular weight in some regions (Fig. 2;
middle panel). Intact brain tissue regions observed on H&E
and MHC were also seen to be containing vasculature filled
with FITC-dextran and Evans blue. A control unablated
tumor that occupied both cortical and subcortical regions is
shown for comparison (Fig. 2; bottom panel).
Figure 3 illustrates the DCE-MRI parameter maps generated from the study shown in Fig. 2. Both pre-LITT and
post-LITT maps are shown for comparison. Mean parameter
values (along with their respective standard error of mean)
of all measured MRI parameters derived from these maps
are shown in Fig. 4.
Peri-ablation enhancement was a common occurrence following LITT with little tumor blood flow in the ablated zone.
Another example is shown in Fig. 5. The ablation was clearly
visible with its boundaries confined to the extent of tumor
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the adjacent brain tissue showed slightly edematous neuropil with GFAP-positive reactive astrocytes. These reactive
astrocytes were dispersed in the neuropil, and an astroglial
scar was not present.

Discussion

Fig. 2  Examples of pre-laser interstitial thermal therapy (LITT),
acute post-LITT and post-LITT 24-h T1 enhancement, cerebral blood
flow (CBF) (top panel) and corresponding histology and fluorescence images (middle panel) with a control, unablated tumor shown
for comparison in the bottom panel. The first row of images in the
top panel show pre-LITT T1 subtraction and CBF images, the middle row T1 subtraction done following LITT and the third row, postLITT 24-h t1 subtraction and CBF. Note the intra-tumoral T1 contrast
brightness in the pre-LITT tumor that shifts to the peri-ablation area
after LITT. Blood flow in the tumor is decreased significantly after
ablation suggesting tissue thermal coagulation. The hematoxylin and
eosin (H&E) and major histocompatibility complex (MHC) histologies and the fluorescence image from this study shown in the middle panel confirm the ablation of bulk of tumor tissue observed on
pre-LITT magnetic resonance imaging. They also show a well-demarcated ablation zone with normal-looking brain parenchyma around it.
Note the presence of an intact sliver of cortical layer above the tumor
preserved after ablation and seen in H&E and MHC images. The fluorescence section is a blend of green fluorescein isothiocyanate and
red Evans blue fluorophores and, thus, yellowish. In comparison, an
unablated tumor shows a solid, space-occupying tumor with central
necrosis and leakage of Evans blue (bottom panel)

tissue observed on pre-LITT MRI. Histologies confirmed
the MRI observations. Both H&E and MHC-stained brain
sections showed near complete ablation of vital tumor mass
with sharp ablation margins. MHC staining also showed
clusters of surviving, positively staining tumor cells just
adjacent to the ablation border. The peri-ablation border of

These data demonstrate that Visualase, a clinical LITT
apparatus, can be employed to ablate primary orthotopic
glioma tumors in rats. The procedure proved to be efficient
and safe, and all the rats survived the procedure. Most of
the tumor tissue could be subjected to cytoablation with the
peri-ablation brain tissue appearing macroscopically normal.
However, microscopic histological analysis showed a transition zone with the neuropil immediately adjacent to the ablation regions demonstrating astrogliosis and edema. These
peri-ablation brain tissue features are comparable to reported
post-LITT histopathological observations after laser ablation
of a newly diagnosed GBM tumor [7].
MRI-guided LITT has emerged as a minimally invasive
technique to treat brain tumors [1, 15, 16, 32]. Tumor/tissue ablation can be tracked in real time with concurrent,
intra-operative MRI, thus obtaining precise margins with
prompt recovery and minimal surgical side effects when
compared to traditional tumor debulking techniques that
require a craniotomy. It is often used for cytoreduction of
recurrent HGG and for primary brain tumors in eloquent
brain regions where traditional surgical techniques are contraindicated [22]. Apart from these advantages, one study
has reported post-ablation blood–brain barrier (BBB) breakdown in patients with recurrent HGG after LITT [20]. The
Ktrans in the peri-ablation region, an MRI index of the rate
constant at which vascular fluids pass into the interstitium,
peaked immediately post-ablation, then slowly decreased
over the next 4 weeks in these patients. This long-lasting
and localized peri-ablation BBB breakdown may provide a
unique opportunity to overcome the barrier to tumor drug
delivery. It has been consistently observed that aggressive
GBM recurrence occurs close to the resected primary tumor
margin in a majority of GBM patients [14, 19, 28]. Similar persistence of tumor cells in the peri-ablation regions
after LITT therapy for primary GBM has been also reported
recently [7]. Therefore, persistent BBB opening in such areas
is relevant to anti-tumor drug delivery [21]. The approach
presented in this study with post-LITT survival of glioma
cells in ablation vicinity can be a good preclinical model
to study drug delivery to such cells during increased periablation vascular permeability and, with long-term monitoring, GBM recurrence. In this regard, our model replicates
several findings on post-LITT histopathology of a human
GBM [7]. These authors also reported that LITT caused a
concentric destruction of tumor and tissue with viable tumor
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Fig. 3  A complete set of magnetic resonance imaging (MRI) parameter maps generated from the dynamic contrast-enhanced MRI
sequences from the ablation study shown in Fig. 2 (n = 5). The top
row shows pre-laser interstitial thermal therapy (LITT) data and the
bottom row, the post-LITT data (from left to right: vascular plasma

Fig. 4  Indices of vascular status measured by dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) at pre-laser and
post-laser interstitial thermal therapy (LITT) sessions. These measures were obtained from the model 3 region following a model selection analysis of the DCE-MRI data (see Appendix for methods). No
statistically different changes were observed at post-LITT imaging
compared to the pre-LITT values. However, persistence of Ktrans suggesting increased blood–brain barrier permeability at both times is
notable; the pre-LITT increase is expected due to leaky tumor-associated vasculature, but the post-ablation Ktrans is observed in the periablation regions in the normally impermeable normal brain vasculature. Cerebral blood flow also increased after ablation consistent with
the hyperemia observed after LITT. Flux is a novel, recently reported
DCE-MRI parameter and is a measure of fluid flow; increase in flux
observed here may be due to hyperemia because Ktrans, the index of
increased permeability, did not change significantly (units of measurements: CBF (× 102), ml.[min−1]; Ktrans, min−1; flux (× 10−1), μm3/
μm2.[s]; vp, ve and VD are % values)

cells just beyond the zones of central necrosis and granulation; in addition, GFAP-positive astrocytes were found
immediately beyond [7].
One report has described tumor cell death in vitro even at
sublethal temperatures [13]. But, natural heat sinks available
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distribution volume, vp; blood-to-brain forward volumetric transfer
constant, Ktrans; extravascular distribution volume, ve; interstitial volume fraction, VD; and the model selection map). Intra-tumorally distributed pixels with elevated values for these parameters during preLITT session, shift to the peri-ablation areas at 24 h

in a live brain such as ongoing blood flow and fluid-filled
cisterns seem to be efficient in heat dissipation in vivo and
prevent cell death in the ablation penumbra. The effects of
laser ablation of tumor tissue have been reported in a mouse
brain tumor model [31]. Cortical GL261 or MGG8 tumors
were localized by bioluminescence and ablated on bench
without the cooling jacket for the laser fiber. These studies were done using a Nd-YAG laser fiber set to 2 W and
laser energy delivered up to 3 min with an accompanying
temperature probe. The laser was switched on and off to
maintain peri-ablation temperature at 43 °C. Pre-LITT and
post-LITT MRI showed ablation of tumor tissue with periablation increases in BBB permeability. The present data
confirm some of these observations and, in addition, demonstrate that LITT under imaging guidance is adaptable to
animal models of glioma that will allow precise ablation of
tumors typically implanted subcortically.

Study limitations
While our method worked as anticipated, slight alterations
were necessary. First, the cooling jacket employed in human
glioma ablations could not be used because it would increase
the diameter of the probe making it impractical for rat brain.
However, the combination of low energy setting and short
ablation duration required for the rat glioma overcame this limitation and led to efficient tumor cytoablation while preserving
the peri-ablation brain tissue. Second, the clinical LITT procedures are carried out via temperature monitoring under MRIthermometry used with custom-written software that could not
be imported onto the animal MRI system. An available glass
fiberoptic temperature sensor was not amenable to bending at
an acute angle for insertion along with the laser fiber into the
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Fig. 5  Representative magnetic
resonance images (A, B) with
their 24-h post-laser interstitial thermal therapy (LITT)
histologies from one study (C,
D). Note the sharp ablation
border with little damage to the
surrounding normal brain tissue
in both hematoxylin & eosin
(H&E) and major histocompatibility complex (MHC) stained
sections (C, D). Near complete
ablation of the main/vital tumor
mass can be seen in them. However, a cluster of tumor cells
staining positive for MHC is
clearly visible in the lateral periablation area (oval in D). Their
proximity to the primary tumor
suggests they may represent the
cells that will lead to glioma
recurrence in due course. Also
note that these cells are within
the contrast-enhancing periablation zone observed in 5B.
High magnification images from
the H&E-stained brain section
and glial fibrillary acid protein
staining are shown in A1, A2,
B1, B2 and A3. A1 and B1 are
from ipsilateral parietal cortex
farther away from ablation. The
neuropil is even (A1) and shows
no reactive astrogliosis (B1).
In contrast, the neuropil next to
the distinct ablation border (B1)
shows astrogliosis (B2) and is
slightly edematous (A3)

rat brain within the confines of the MRI apparatus to achieve
concurrent temperature measurements. To compensate, we
confirmed in preliminary studies that the peri-ablation zone
temperature rose only to sublethal levels by positioning the
temperature probe 4 mm away from the laser fiber tip and then
measuring changes in temperature during tumor ablation for
tabletop standardization of the methods (see Appendix). Third,
the U251 GBM model employed in this study represented only
the space-occupying, contrast-enhancing glioma phenotype.
While it helped in defining tumor borders to achieve sharp
ablation margins, we note that this model lacks the infiltrative component and genetic variability seen in clinical GBM.
Thus, although the extent of post-LITT contrast enhancement
and edema formation seemed enough to encompass the tumor

cells that survived the ablation procedure in this glioma model,
infiltrating tumor cells may remain even beyond this sublethal temperature zone. Therefore, a future requirement for this
approach is the need to employ it using patient-derived orthotopic xenograft models for GBM reported to reproduce both
the genetic and phenotypic fidelity to human disease [2, 26].

Conclusions
We present the feasibility of preclinical adaptation of a
clinically used, imaging-guided glioma cytoablation by
LITT. LITT performed in human patients involves the use
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of phase imaging, for which real-time thermometry can
be extracted. Due to technical limitations with use of the
animal MRI, we were unable to perform real-time MR
thermometry but instead used DWI which can be obtained
in real time to monitor the extent of ablation. DWI is part
of the routine sets of clinical images obtained post-LITT
and has been demonstrated to correlate with extent of ablation as measured by the thermal damage estimate provided
by the platform software and post-ablation T1 with gadolinium imaging [4]. This is a potential method of performing MRI-guided tumor debulking in preclinical orthotopic
glioma models thus recreating the clinical approach in the
laboratory for increased translational applicability.
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00701-021-05002-y.
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Comments Magnetic resonance imaging-guided laser interstitial
thermal therapy (LITT), which is a relatively new treatment option
especially in Europe already now has immensely expanded the
neurosurgical arsenal and will surely find many more applications in
the future. Nagaraja et al. have here added an interesting and carefully
conducted animal study to the literature on laser ablation. The approach
and implementation of the model are promising, but its transferability
to clinical application in human must certainly be critically assessed,
especially neuropathologically regarding boundaries between tumor
and adjacent brain tissue without the infiltrative component and genetic
variability of conventional glioblastomas, and technically regarding
the differences in the type and performance of LITT application in
the animal model and in glioma patients. Nevertheless, I would like to
congratulate the authors for their important work and wish them that
their model and results will contribute both to a better understanding
of the fundamentals of LITT, and to further improvement of its clinical
applications.
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